1
|
Zhang J, Sun B, Shen W, Wang Z, Liu Y, Sun Y, Zhang J, Liu R, Wang Y, Bai T, Ma Z, Luo C, Qiao X, Zhang X, Yang S, Sun Y, Jiang D, Yang K. In Silico Analyses, Experimental Verification and Application in DNA Vaccines of Ebolavirus GP-Derived pan-MHC-II-Restricted Epitopes. Vaccines (Basel) 2023; 11:1620. [PMID: 37897022 PMCID: PMC10610722 DOI: 10.3390/vaccines11101620] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2023] [Revised: 10/08/2023] [Accepted: 10/10/2023] [Indexed: 10/29/2023] Open
Abstract
(1) Background and Purpose: Ebola virus (EBOV) is the causative agent of Ebola virus disease (EVD), which causes extremely high mortality and widespread epidemics. The only glycoprotein (GP) on the surface of EBOV particles is the key to mediating viral invasion into host cells. DNA vaccines for EBOV are in development, but their effectiveness is unclear. The lack of immune characteristics resides in antigenic MHC class II reactivity. (2) Methods: We selected MHC-II molecules from four human leukocyte antigen II (HLA-II) superfamilies with 98% population coverage and eight mouse H2-I alleles. IEDB, NetMHCIIpan, SYFPEITHI, and Rankpep were used to screen MHC-II-restricted epitopes with high affinity for EBOV GP. Further immunogenicity and conservation analyses were performed using VaxiJen and BLASTp, respectively. EpiDock was used to simulate molecular docking. Cluster analysis and binding affinity analysis of EBOV GP epitopes and selected MHC-II molecules were performed using data from NetMHCIIpan. The selective GP epitopes were verified by the enzyme-linked immunospot (ELISpot) assay using splenocytes of BALB/c (H2d), C3H, and C57 mice after DNA vaccine pVAX-GPEBO immunization. Subsequently, BALB/c mice were immunized with Protein-GPEBO, plasmid pVAX-GPEBO, and pVAX-LAMP/GPEBO, which encoded EBOV GP. The dominant epitopes of BALB/c (H-2-I-AdEd genotype) mice were verified by the enzyme-linked immunospot (ELISpot) assay. It is also used to evaluate and explore the advantages of pVAX-LAMP/GPEBO and the reasons behind them. (3) Results: Thirty-one HLA-II-restricted and 68 H2-I-restricted selective epitopes were confirmed to have high affinity, immunogenicity, and conservation. Nineteen selective epitopes have cross-species reactivity with good performance in MHC-II molecular docking. The ELISpot results showed that pVAX-GPEBO could induce a cellular immune response to the synthesized selective peptides. The better immunoprotection of the DNA vaccines pVAX-LAMP/GPEBO coincides with the enhancement of the MHC class II response. (4) Conclusions: Promising MHC-II-restricted candidate epitopes of EBOV GP were identified in humans and mice, which is of great significance for the development and evaluation of Ebola vaccines.
Collapse
Affiliation(s)
- Junqi Zhang
- Department of Immunology, Basic Medicine School, Air-Force Medical University (The Fourth Military Medical University), Xi’an 710032, China; (J.Z.); (B.S.); (W.S.); (Z.W.); (Y.S.); (J.Z.); (R.L.); (Y.W.); (T.B.); (Z.M.); (C.L.); (X.Q.); (X.Z.); (S.Y.); (Y.S.)
| | - Baozeng Sun
- Department of Immunology, Basic Medicine School, Air-Force Medical University (The Fourth Military Medical University), Xi’an 710032, China; (J.Z.); (B.S.); (W.S.); (Z.W.); (Y.S.); (J.Z.); (R.L.); (Y.W.); (T.B.); (Z.M.); (C.L.); (X.Q.); (X.Z.); (S.Y.); (Y.S.)
- Yingtan Detachment, Jiangxi Corps, Chinese People’s Armed Police Force, Yingtan 335000, China
| | - Wenyang Shen
- Department of Immunology, Basic Medicine School, Air-Force Medical University (The Fourth Military Medical University), Xi’an 710032, China; (J.Z.); (B.S.); (W.S.); (Z.W.); (Y.S.); (J.Z.); (R.L.); (Y.W.); (T.B.); (Z.M.); (C.L.); (X.Q.); (X.Z.); (S.Y.); (Y.S.)
| | - Zhenjie Wang
- Department of Immunology, Basic Medicine School, Air-Force Medical University (The Fourth Military Medical University), Xi’an 710032, China; (J.Z.); (B.S.); (W.S.); (Z.W.); (Y.S.); (J.Z.); (R.L.); (Y.W.); (T.B.); (Z.M.); (C.L.); (X.Q.); (X.Z.); (S.Y.); (Y.S.)
| | - Yang Liu
- Institute of AIDS Prevention and Control, Shaanxi Provincial Center for Disease Control and Prevention, Xi’an 710054, China;
| | - Yubo Sun
- Department of Immunology, Basic Medicine School, Air-Force Medical University (The Fourth Military Medical University), Xi’an 710032, China; (J.Z.); (B.S.); (W.S.); (Z.W.); (Y.S.); (J.Z.); (R.L.); (Y.W.); (T.B.); (Z.M.); (C.L.); (X.Q.); (X.Z.); (S.Y.); (Y.S.)
| | - Jiaxing Zhang
- Department of Immunology, Basic Medicine School, Air-Force Medical University (The Fourth Military Medical University), Xi’an 710032, China; (J.Z.); (B.S.); (W.S.); (Z.W.); (Y.S.); (J.Z.); (R.L.); (Y.W.); (T.B.); (Z.M.); (C.L.); (X.Q.); (X.Z.); (S.Y.); (Y.S.)
| | - Ruibo Liu
- Department of Immunology, Basic Medicine School, Air-Force Medical University (The Fourth Military Medical University), Xi’an 710032, China; (J.Z.); (B.S.); (W.S.); (Z.W.); (Y.S.); (J.Z.); (R.L.); (Y.W.); (T.B.); (Z.M.); (C.L.); (X.Q.); (X.Z.); (S.Y.); (Y.S.)
| | - Yongkai Wang
- Department of Immunology, Basic Medicine School, Air-Force Medical University (The Fourth Military Medical University), Xi’an 710032, China; (J.Z.); (B.S.); (W.S.); (Z.W.); (Y.S.); (J.Z.); (R.L.); (Y.W.); (T.B.); (Z.M.); (C.L.); (X.Q.); (X.Z.); (S.Y.); (Y.S.)
| | - Tianyuan Bai
- Department of Immunology, Basic Medicine School, Air-Force Medical University (The Fourth Military Medical University), Xi’an 710032, China; (J.Z.); (B.S.); (W.S.); (Z.W.); (Y.S.); (J.Z.); (R.L.); (Y.W.); (T.B.); (Z.M.); (C.L.); (X.Q.); (X.Z.); (S.Y.); (Y.S.)
| | - Zilu Ma
- Department of Immunology, Basic Medicine School, Air-Force Medical University (The Fourth Military Medical University), Xi’an 710032, China; (J.Z.); (B.S.); (W.S.); (Z.W.); (Y.S.); (J.Z.); (R.L.); (Y.W.); (T.B.); (Z.M.); (C.L.); (X.Q.); (X.Z.); (S.Y.); (Y.S.)
| | - Cheng Luo
- Department of Immunology, Basic Medicine School, Air-Force Medical University (The Fourth Military Medical University), Xi’an 710032, China; (J.Z.); (B.S.); (W.S.); (Z.W.); (Y.S.); (J.Z.); (R.L.); (Y.W.); (T.B.); (Z.M.); (C.L.); (X.Q.); (X.Z.); (S.Y.); (Y.S.)
| | - Xupeng Qiao
- Department of Immunology, Basic Medicine School, Air-Force Medical University (The Fourth Military Medical University), Xi’an 710032, China; (J.Z.); (B.S.); (W.S.); (Z.W.); (Y.S.); (J.Z.); (R.L.); (Y.W.); (T.B.); (Z.M.); (C.L.); (X.Q.); (X.Z.); (S.Y.); (Y.S.)
| | - Xiyang Zhang
- Department of Immunology, Basic Medicine School, Air-Force Medical University (The Fourth Military Medical University), Xi’an 710032, China; (J.Z.); (B.S.); (W.S.); (Z.W.); (Y.S.); (J.Z.); (R.L.); (Y.W.); (T.B.); (Z.M.); (C.L.); (X.Q.); (X.Z.); (S.Y.); (Y.S.)
| | - Shuya Yang
- Department of Immunology, Basic Medicine School, Air-Force Medical University (The Fourth Military Medical University), Xi’an 710032, China; (J.Z.); (B.S.); (W.S.); (Z.W.); (Y.S.); (J.Z.); (R.L.); (Y.W.); (T.B.); (Z.M.); (C.L.); (X.Q.); (X.Z.); (S.Y.); (Y.S.)
| | - Yuanjie Sun
- Department of Immunology, Basic Medicine School, Air-Force Medical University (The Fourth Military Medical University), Xi’an 710032, China; (J.Z.); (B.S.); (W.S.); (Z.W.); (Y.S.); (J.Z.); (R.L.); (Y.W.); (T.B.); (Z.M.); (C.L.); (X.Q.); (X.Z.); (S.Y.); (Y.S.)
| | - Dongbo Jiang
- Department of Immunology, Basic Medicine School, Air-Force Medical University (The Fourth Military Medical University), Xi’an 710032, China; (J.Z.); (B.S.); (W.S.); (Z.W.); (Y.S.); (J.Z.); (R.L.); (Y.W.); (T.B.); (Z.M.); (C.L.); (X.Q.); (X.Z.); (S.Y.); (Y.S.)
- Institute of AIDS Prevention and Control, Shaanxi Provincial Center for Disease Control and Prevention, Xi’an 710054, China;
| | - Kun Yang
- Department of Immunology, Basic Medicine School, Air-Force Medical University (The Fourth Military Medical University), Xi’an 710032, China; (J.Z.); (B.S.); (W.S.); (Z.W.); (Y.S.); (J.Z.); (R.L.); (Y.W.); (T.B.); (Z.M.); (C.L.); (X.Q.); (X.Z.); (S.Y.); (Y.S.)
- The Key Laboratory of Bio-Hazard Damage and Prevention Medicine, Basic Medicine School, Air-Force Medical University (The Fourth Military Medical University), Xi’an 710032, China
- Department of Rheumatology, Tangdu Hospital, Air-Force Medical University (The Fourth Military Medical University), Xi’an 710038, China
| |
Collapse
|
2
|
Sun B, Zhang J, Li Z, Xie M, Luo C, Wang Y, Chen L, Wang Y, Jiang D, Yang K. Integration: Gospel for immune bioinformatician on epitope-based therapy. Front Immunol 2023; 14:1075419. [PMID: 36798136 PMCID: PMC9927647 DOI: 10.3389/fimmu.2023.1075419] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2022] [Accepted: 01/17/2023] [Indexed: 02/04/2023] Open
Affiliation(s)
- Baozeng Sun
- Department of Immunology, Basic Medicine School, Air-Force Medical University (the Fourth Military Medical University), Xi'an, Shaanxi, China
| | - Junqi Zhang
- Department of Immunology, Basic Medicine School, Air-Force Medical University (the Fourth Military Medical University), Xi'an, Shaanxi, China
| | - Zhikui Li
- Department of Immunology, Basic Medicine School, Air-Force Medical University (the Fourth Military Medical University), Xi'an, Shaanxi, China
| | - Mingyang Xie
- Department of Immunology, Basic Medicine School, Air-Force Medical University (the Fourth Military Medical University), Xi'an, Shaanxi, China
| | - Cheng Luo
- Department of Immunology, Basic Medicine School, Air-Force Medical University (the Fourth Military Medical University), Xi'an, Shaanxi, China
| | - Yongkai Wang
- Department of Immunology, Basic Medicine School, Air-Force Medical University (the Fourth Military Medical University), Xi'an, Shaanxi, China
| | - Longyu Chen
- Department of Immunology, Basic Medicine School, Air-Force Medical University (the Fourth Military Medical University), Xi'an, Shaanxi, China
| | - Yueyue Wang
- Department of Immunology, Basic Medicine School, Air-Force Medical University (the Fourth Military Medical University), Xi'an, Shaanxi, China
| | - Dongbo Jiang
- Department of Immunology, Basic Medicine School, Air-Force Medical University (the Fourth Military Medical University), Xi'an, Shaanxi, China.,The Key Laboratory of Bio-hazard Damage and Prevention Medicine, Basic Medicine School, Air-Force Medical University (the Fourth Military Medical University), Xi'an, Shaanxi, China.,Department of Microbiology, Basic Medicine School, Air-Force Medical University (the Fourth Military Medical University), Xi'an, Shaanxi, China
| | - Kun Yang
- Department of Immunology, Basic Medicine School, Air-Force Medical University (the Fourth Military Medical University), Xi'an, Shaanxi, China.,The Key Laboratory of Bio-hazard Damage and Prevention Medicine, Basic Medicine School, Air-Force Medical University (the Fourth Military Medical University), Xi'an, Shaanxi, China.,Department of Rheumatology, Tangdu Hospital, Air-Force Medical University (the Fourth Military Medical University), Xi'an, Shaanxi, China
| |
Collapse
|
3
|
Whole Proteome-Based Therapeutic Targets Annotation and Designing of Multi-Epitope-Based Vaccines against the Gram-Negative XDR-Alcaligenes faecalis Bacterium. Vaccines (Basel) 2022; 10:vaccines10030462. [PMID: 35335094 PMCID: PMC8955209 DOI: 10.3390/vaccines10030462] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2022] [Revised: 03/11/2022] [Accepted: 03/14/2022] [Indexed: 12/29/2022] Open
Abstract
This study involved therapeutic targets mining for the extremely drug-resistant bacterial species called Alcaligenes faecalis, which is known to infect humans. The infections caused by this species in different parts of the human body have been linked with a higher degree of resistance to several classes of antibiotics. Meanwhile, alternate therapeutic options are needed to treat these bacterial infections in clinical settings. In the current study, a subtractive proteomics approach was adapted to annotate the whole proteome of Alcaligenes faecalis and prioritize target proteins for vaccine-related therapeutics design. This was followed by targeted protein-specific immune epitope prediction and prioritization. The shortlisted epitopes were further subjected to structural design and in silico validation of putative vaccines against Alcaligenes faecalis. The final vaccine designs were also evaluated for potential interaction analysis with human TLR-2 through molecular docking. Finally, the putative vaccines were subjected to in silico cloning and immune simulation approaches to ensure the feasibility of the target-specific vaccine constructs in further experimental designs.
Collapse
|